Skip to content | Change text size
 

Professor Christopher JH Porter

Associate Professor Chris Porter

Professor of Pharmaceutics
Associate Dean (Research)
Theme leader, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences

BPharm University of Nottingham (UK)
PhD University of Nottingham (UK)

Telephone: +61 3 9903 9649
Fax: +61 3 9903 9583
Email: chris.porter@pharm.monash.edu.au

Theme leader, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences

Research interests

  • Oral drug delivery, bioavailability enhancement and lymphatic drug transport
  • Lipid-based formulation design and assessment
  • Drug interactions with intracellular binding proteins
  • Nanomedicines, in particular dendrimer-based drug delivery

Education

  • Biopharmaceutical principles of drug delivery (VCP 4032)
  • Drug delivery system design (VPS 3081)
  • Pharmacokinetic implications of hepatic and renal failure (VCP 3031)

Representative publications

  1. Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Porter CJH, et.al. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res. 2009 (in press)
  2. Katneni K, Charman SA, Porter CJH. Use of plasma proteins as solubilizing agents in in vitro permeability experiments: correction for unbound drug concentration using the reciprocal permeability approach. J Pharm Sci. 2008; 97:209-224.
  3. Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Porter, CJH et.al. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm. 2008; 5:449-463.
  4. Cuine JF, Charman WN, Pouton CW, Edwards GA, Porter CJH. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci. 2008; 97:995-1012.
  5. Chuang S, Velkov T, Horne J, Porter CJH, Scanlon MJ. Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008; 51:3755-3764.
  6. Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv. 2008; 60:702-716.
  7. Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv. 2008; 60:625-637.
  8. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv. 2008; 60:673-691.
  9. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007; 6:231-248.
  10. Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJH, Charman SA. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos. 2007; 35:2211-2217.)
  11. Kossena GA, Charman WN, Wilson CG, O'Mahony B, Lindsay B, Porter CJH, et.al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res. 2007; 24:2084-2096.
  12. Katneni K, Charman SA, Porter CJH. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci. 2007; 96:280-293.
  13. Velkov T, Horne J, Laguerre A, Jones E, Scanlon MJ, Porter CJH.  Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay. Chem Biol. 2007; 14(4):453-465.
  14. Kaminskas LM, Boyd BJ, Karellas P, Henderson SA, Giannis MP, Porter CJH, et.al. Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition. Mol Pharm. 2007; 4:949-961.
  15. Cuine JF, Charman WN, Pouton CW, Edwards GA, Porter CJH. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm Res. 2007; 24:748-757.
  16. Boyd BB, Khoo SM, Whittaker DV, Davey G, Porter CJH. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. Int J Pharm. 2007; 340:52-60.
  17. Trevaskis NL, Porter CJH, Charman WN. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J Pharmacol Exp Ther. 2006; 316:881-891.
  18. Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJH. Cationic poly-l-lysine dendrimers: pharmacokinetics, biodistribution and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharmaceut. 2006; 3:614-627.
  19. Velkov T, Chuang S, Wielens J, Sakellaris H, Charman WN, Porter CJH, et.al. The interaction of lipophilic drugs with intestinal fatty acid binding protein. J Biol Chem. 2005; 280:17769-17776.
  20. Segrave A, Mager DE, Charman SA, Edwards GA, Porter CJH. Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep. J Pharmacol Exp Ther. 2004; 309:1085-1092.

External appointments

Editorial board member:
  • Pharmaceutical Research
  • Journal of Pharmaceutical Sciences
  • Journal of Pharmacy and Pharmacology